Australian recommendations for the management of hepatocellular carcinoma
Authors: John S Lubel, Stuart K Roberts, Simone I Strasser and Nick Shackel
Published online: 4 October 2021
In reply: We welcome the comments raised by Braillon1 regarding the contribution of smoking to the risk of hepatocellular carcinoma (HCC).
We have the following comments. Firstly, the Australian recommendations for the management of HCC are a consensus statement developed by multiple stakeholders representing peak organisations. In addition to hepatologists, oncologists, palliative care physicians, radiologists and surgeons produced the statement.2 The full list of contributors is listed in the acknowledgement section.
Secondly, due to journal limitations on space, the published article focused on the most significant issues relating to the diagnosis and management of HCC and provided context for the listed recommendations. Smoking is a modifiable contributor to HCC development, and the published manuscript highlights the importance of smoking cessation in Box 3 (where smoking cessation is listed as a modifiable risk factor) and Box 6.2
Thirdly, the health impacts of smoking are not disputed. Fortunately, between 1991 and 2019, the proportion of daily smokers in Australia has halved.3 While smoking is likely to have a negative impact on HCC, this has not been demonstrated in prospective controlled studies and currently does not appear in any risk calculators. This is in part due to the quality of evidence, which is largely derived from epidemiological cohort studies that may be vulnerable to confounding variables such as socio‐economic factors, including alcohol use, and the known association of smoking with advanced hepatic fibrosis.4 Despite the lack of high level evidence, our position is to advocate smoking cessation in any individual at risk from HCC.
Lastly, consensus statements by their very nature cover topics less well studied, and provide expert clinician input using Delphi methodology to synthesise sparse or conflicting data with the purpose of providing practical guidance.5,6 It is therefore not surprising that nine of the recommendations are derived from level A evidence. Although only four recommendations focus on surveillance, the accompanying Box 2 and Box 3 provide additional details on this topic for the reader.
The authors’ aim was to raise awareness and provide an overview of the important aspects of HCC management to the general readership of the MJA. We are very grateful for Braillon’s comments in highlighting the issue of smoking in patients at risk from and diagnosed with HCC.
Competing interests
References
- Braillon A. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement [letter]. Med J Aust 2021; 215: 000–000.
- Lubel JS, Roberts SK, Strasser SI, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021; 214: 475–483. https://www.mja.com.au/journal/2021/214/10/australian-recommendations-management-hepatocellular-carcinoma-consensus
- Australian Institute of Health and Welfare 2020. National Drug Strategy Household Survey 2019 [Cat. No. PHE 270]. Canberra: AIHW. 2020. https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/summary (viewed Aug 2021).
- Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology 2006; 44: 1394–1396.
- Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 376–380.
- Raine R, Sanderson C, Black N. Developing clinical guidelines: a challenge to current methods. BMJ 2005; 331: 631–633.
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan